preparation of KANJINTI, refer to the package insert or call Herceptin (trastuzumab) Prescribing Information [revised 2024], Genentech.
Kanjinti is a biosimilar medicinal product. It is highly similar to the reference product Herceptin (trastuzumab), which was authorised in the
Herceptin 21 mg/ml IV and anastrozole at administration. For the anastrozole dose, refer to the anastrozole package insert. Three weekly
Trastuzumab (Herceptin) label/2024/ s004lbl.pdf. Accessed Herceptin product availability for multi-dose vial corrected from 420.
Official answer: What is Herceptin? Herceptin (generic name: trastuzumab) is an anticancer drug. Is Herceptin a chemo drug? No
Attachment 1: Product information for AusPAR Herceptin Trastuzumab Roche Products package inserts of validated FISH, CISH and SISH assays.
In vitro, trastuzumab product mediated ADCC has been shown to be preferentially exerted on HER2 Herceptin [package insert]. Genentech, Inc
Herceptin [package insert]. South San Francisco, CA; Genentech, Inc Product Information: HERCEPTIN HYLECTA subcutaneous injection
Herceptin [package insert]. South San Francisco, CA: Genentech, Inc.; November 2024. 2. Kanjinti [package insert]. Thousand Oaks, CA: Amgen, Inc.; June 2024
Comments